Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion type Assertion NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_head.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion description "[before RRBSO and with no clinical signs of ovarian cancer) CA125 level was 9.0 U/ml (range 2-78) and was 10.0 U/ml (range 1-43) in 115 BRCA2 mutation carriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_provenance.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion evidence source_evidence_literature NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_provenance.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion SIO_000772 24389956 NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_provenance.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion wasDerivedFrom befree-20150227 NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_provenance.
- NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_assertion wasGeneratedBy ECO_0000203 NP962686.RAmXH8P3ZBkE3-RMkOwiELcgvc9A4Pm-fetVf_BSspEV0130_provenance.